




PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>C m p l t e i f K n w n</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/632,888
		Filing Date	August 1, 2003
		First Named Inventor	Bentzien, J. et al
		Art Unit	to be assigned 1626
		Examiner Name	to be assigned Stockton
Sheet	1	of	2
		Attorney Docket Number	9/254

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code <sup>2</sup> (if known)				
		US- 4,139,626	02/13/1979	Beard, C.		
		US- 4,191,764	03/04/1980	Beard, C.		
		US- 4,312,873	01/26/1982	Beard, C.		
		US- 5,141,950	08/25/1992	Nakane, M. et al		
		US- 5,180,724	01/19/1993	Bowles, S. et al		
		US- 5,270,148	12/14/1993	Morigaki, M. et al		
		US- 5,541,339	07/30/1996	Kelly, R. et al		
		US- 5,559,127	09/24/1996	Hartman, G. et al		
		US- 5,616,537	04/01/1997	Yokota, S. et al		
		US- 5,770,544	06/23/1998	Yokota, S. et al		
		US- 2003/0144286	07/31/2003	Frenkel, A. et al		
		US- 2003/0125550	07/03/2003	Blume, T. et al		
		US-				
		US-				
	US-					
	US-					
	US-					
	US-					
	US-					

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
[initials]		WO 01/70705 A1	09/27/2001	Alcon Universal Ltd.		
		WO 01/21634 A1	03/29/2001	Trega Biosciences		
[initials]		CA 1094061	01/20/1981	Syntex, Inc.		
		CA 2115737	08/17/1994	Dr. Karl Thomae		
		WO 01/25238	04/12/2001	Boehringer Ingelheim Pharmaceuticals, Inc		
[initials]		WO99/24035	05/02/1999	Bristol-Myers Squibb		
		WO 03/030902	04/14/2003	Tularik, Inc.		
		WO 03/006438	01/23/2003	Schering Akt.		

Examiner Signature	<i>Lam L. Stockton</i>	Date Considered	11/4/04
--------------------	------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/632,888		
		Filing Date	August 1, 2003		
		First Named Inventor	Bentzien, J. et al		
		Group Art Unit	to be assigned 1626		
		Examiner Name	to be assigned Stockton		
Sheet	2	of	2	Attorney Docket Number	9/254

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
JS		FANG, J. et al; 2-Aminobenzimidazoles as Neuropeptide Y Y5 Antagonists: Solution Phase Synthesis and Structure Relationships, ACS National Meeting, Chicago, IL, August 26, 2001. ABSTRACT MEDI 26	
JS		LINN, J., et al; Benzimidazole Neuropeptide Y Y5 Antagonists: Rapid SAR Development Using a Solid-Phase Approach, ACS National Meeting, Chicago, IL August 26, 2001. ABSTRACT MEDI 27	
JS		HEYER, D. et al; Discovery of a Novel Series of Benzimidazole-based Neuropeptide Y Y5 Antagonists from a 7-TM Targeted Chemical Library, ACS National Meeting, Chicago, IL, August 26, 2001. ABSTRACT MEDI 30	
JS		AKWABI-AMEYAW, A. et al; Synthesis and SAR of Substituted 5 Acylamino Benzimidazoles as Potent Neuropeptide Y Y5 Antagonist, - ACS National Meeting, Chicago, IL, August 26 2001. ABSTRACT MEDI KOSTER 33	
JS		KONG, D. et al; Chemical Components of Viscum Coloratum V. Chinese Journal of Pharmaceuticals, 1989, 20(3), pp. 110-115	
JS		Abstracts- American Chemical Society-Division of Medicinal Chemistry - 222nd ACS National Meeting, Chicago, IL - August 26-30, 2001	


Examiner Signature	<i>James L. Stockton</i>	Date Considered	11/4/04
--------------------	--------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08a (08-03)

[illegible]

Examiner Signature	<i>Sam L. Stock</i>	Date Considered	11	4	04
-----------------------	---------------------	--------------------	----	---	----

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.